Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas Review
| Authors: | Epstein-Peterson, Z. D.; Horwitz, S. M. |
| Review Title: | Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas |
| Abstract: | The advent of molecularly targeted agents for patients with peripheral T-cell lymphomas (PTCL) has begun to change the therapeutic landscape in these diseases, especially for patients with relapsed or refractory disease. These agents, grounded in targeting numerous pathways or alterations related to disease pathogenesis, have shown promise across many PTCL subhistologies. Aided by significant advances in experimental techniques related to molecular biology, epigenetics, and immunology, more recent studies have begun elucidating mediators of resistance, both intrinsic and acquired, to inform future therapeutic advances. Defining and targeting these escape mechanisms through rational combination approaches will likely be important to continue to build on these promising advances and further improve clinical outcomes for patients facing PTCL. © 2021 Elsevier Inc. |
| Keywords: | gene mutation; overall survival; histone deacetylase inhibitor; janus kinase 2; lenalidomide; cancer recurrence; cisplatin; doxorubicin; gemcitabine; cell proliferation; carboplatin; interleukin 2; stat3 protein; etoposide; protein serine threonine kinase; phosphatidylinositol 3 kinase; ifosfamide; coughing; fever; rash; b cell lymphoma; peripheral t cell lymphoma; t cell lymphoma; immunology; epigenetics; protein kinase tyk2; molecular biology; pralatrexate; azacitidine; carfilzomib; aurora a kinase; targeted therapies; stat protein; molecular pathology; molecularly targeted therapy; stat5b protein; clinical outcome; anaplastic large cell lymphoma; kinase inhibitors; janus kinase 1; janus kinase 3; protein acetylation; crizotinib; protein kinase syk; histone acetyltransferase; high throughput sequencing; ruxolitinib; alisertib; human; priority journal; article; copanlisib; pembrolizumab; ixazomib; duvelisib; peripheral t-cell lymphomas; epigenetic therapies; immunomodulatory therapies; cerdulatinib; mivavotinib; tenalisib; valemetostat |
| Journal Title: | Seminars in Hematology |
| Volume: | 58 |
| Issue: | 2 |
| ISSN: | 0037-1963 |
| Publisher: | W.B. Saunders Co-Elsevier Inc. |
| Date Published: | 2021-04-01 |
| Start Page: | 78 |
| End Page: | 84 |
| Language: | English |
| DOI: | 10.1053/j.seminhematol.2021.02.004 |
| PUBMED: | 33906725 |
| PROVIDER: | scopus |
| PMCID: | PMC8496899 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 June 2021 -- Source: Scopus |
